Introduction
============

Gastric cancer is one of the common aggressive malignant tumors, with a high ratio of tumor recurrence and mortality [@B1], [@B2]. According to the position of the main tumor, gastric cancer is classified into upper, middle or lower third cancers. Although the pathological characteristics are similar, the position of tumor has an influence on the postoperative quality of life and survival of gastric cancer patients. Adenocarcinoma of the esophagogastric junction (AEG), is a representative malignancy located between the esophagus and stomach, and was originally characterized by Siewert [@B3]. It was well-known to have unique clinicopathological features and biological behavior. In recent decades, the incidence rate of AEG gradually rose globally, particularly in the western countries [@B4], [@B5]. AEG and upper gastric cancer (UGC) patients undergo surgery, a total gastrectomy is usually required. Recent researches have reported that distal gastrectomy provide a better long-term outcome for distal gastric cancer patients compared with total gastrectomy [@B6], [@B7]. Besides some studies have indicated that the prognosis for AEG is worse compare with distal gastric cancer patients [@B8]. Therefore, it is important to search suitable clinical prognostic factors to supply more accurate and precise evaluates of survival, extremely important in high-fatality malignancies such as AEG. This can both enhance outcomes and decrease costs by better choosing patients for eligible treatment [@B9].

Cancer-related systemic inflammatory response plays an important role in the progression and outcome of tumors [@B10], [@B11]. We previously reported that systemic immune-inflammation score SII (SII=N×P∕L), which was based on neutrophil (N), platelet (P) and lymphocyte (L) counts, had been demonstrated to be a predictive prognostic indicator in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy [@B12]. Also, several common inflammation-based prognostic scoring systems, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) have been reported to have prognostic value in various cancers [@B13]-[@B16]. In addition, the hemostatic also plays a key role in cancer progression and metastasis [@B17], [@B18]. Liver-produced fibrinogen is a key factor in the hemostatic cascade. Recent studies have confirmed that fibrinogen correlates with cancer progression, poor response to chemotherapy and adverse prognostic outcome in various malignancies [@B19]-[@B21]. Recently, several researches analyzed a new scoring system, that is, combining preoperative fibrinogen and the NLR (F-NLR). F-NLR has been demonstrated to be a significant prognostic marker in several types of cancers, such as non-small cell lung cancer, esophageal squamous cell carcinoma and gastric cancer [@B22]-[@B24].

Therefore, the current study aimed to evaluate the prognostic value of F-NLR in patients with AEG and UGC.

Materials and Methods
=====================

Patients
--------

Two independent cohorts comprising 356 consecutive patients with AEG or UGC who underwent curative surgery were enrolled into the present retrospective study from Harbin Medical University Cancer Hospital. The training set that included 161 consecutive patients was collected between 2007 and 2011, and the validation set that included 195 consecutive patients was collected between 2012 and 2016 with the same enrolment criteria. The patients enrolled this analysis met the following inclusion criteria: 1) pathologically confirmed adenocarcinoma, 2) no neoadjuvant chemotherapy and/or radiotherapy before operation, 3) complete clinicopathologic parameters and outcome. The major exclusion criteria included: 1) multiple primary malignances, 2) hematological disease, bone marrow disease and autoimmune disease, 3) active infection or other inflammatory disease for nearly 1 month before surgery, 4) death within perioperative period. The Siewert classification was introduced to about tumor position [@B3]. According to previous published reports, [@B25], [@B26] AEG was well- defined as Siewert type I, II, and III tumors and tumors with the center was situate exceed 5 cm below the gastroesophageal junction within the upper one third stomach as UGC. Clinicopathological parameters and laboratory inspections of the patients were acquired from the medical records, including sex, age, tumor size, tumor location, histologic differentiation, surgical procedure, pTNM stage and blood cell count. The pTNM stage was according to the 8th TNM classification of American Joint Committee on Cancer (AJCC) staging manual. Permission for this retrospective cohort research was approved by the ethics committee of Harbin Medical University Cancer Hospital.

Evaluation of prognostic scores
-------------------------------

Hematological laboratory measurements including neutrophil count, lymphocyte count, monocyte count and fibrinogen concentrations, were extracted from the daily blood test administered in the week before surgery. According to the Youden index by Receiver operating characteristic (ROC) curve, the most appropriate cutoff threshold was found as 3.09g/L for plasma fibrinogen and 1.84 for NLR in the training cohort, and was then applied to the validation cohort. For these values, an area under the curve (AUC) as 0.650( 95%CI: 0.565-0.735) and 0.615(95% CI:0.527-0.702), respectively. Similarly, the optimal cutoff values of 110, 451 and 3.25 for PLR, SII and LMR also determined by ROC curve. Based on these cut-off values, the F-NLR score was classified as follows: F-NLR score of 2 \[both a hyperfibrinogenemia (≥3.09g/L) and high NLR (≥1.84)\], 1 \[either hyperfibrinogenemia (≥3.09g/L) or high NLR (≥1.84)\], 0 \[neither hyperfibrinogenemia nor high NLR\].

Statistical analysis
--------------------

Statistical analysis was done using SPSS software version 22 (IBM, Armonk, New York, USA). A two-tailed chi-squared test and Spearman-rho test was used to evaluate differences in categorical variables. Differences between the overall survival (OS) generated by the Kaplan-Meier curves were decided using the log-rank test. OS was defined as the time in months between the date of surgery and the date of death or last follow-up. Univariate and multivariate analyses were carried out by Cox regression models to clarify the independent prognostic factors. Prognostic value and accuracy of the F-NLR prognostic models was assessed by receiver operating characteristic (ROC) analysis. All *P* values were quoted two-sided, and a *P* value of \<0.05 was considered to represent statistically significant.

Results
=======

Patient characteristics
-----------------------

Baseline characteristics clinicopathological of patients are illustrated in Table [1](#T1){ref-type="table"}. In the training cohort, 161 patients (126 men \[78.3%\] and 35 women \[21.7%\]) were included. The median age was 61 (range 34-76) years. The median and mean follow-up duration were 43.7 and 52.6 months, respectively. In the validation cohort, 195 patients (154 men \[79.0%\] and 41 women \[21.0%\]) were included. The median age was 62 (range 32-76) years. The median and mean follow-up duration were 49.8 and 54.7 months, respectively.

Due to the limitation of patient number, we combined the training and the validation cohorts to the combined cohort. The relationship between F-NLR and clinicopathological variables is shown in Supplementary Table [S1](#SM0){ref-type="supplementary-material"}. There was significant correlation of F-NLR with tumor size, PLR, LMR and SII in all 3 cohorts.

Prognostic analysis based on plasma fibrinogen, NLR or F-NLR
------------------------------------------------------------

We conducted the Kaplan-Meier analysis and log-rank test to determine the survival differences between the groups categorized by fibrinogen, NLR or F-NLR. Patients with hyperfibrinogenemia had a much worse OS than those with low fibrinogen (*P*\<0.001 in all 3 sets; Figure [S1](#SM0){ref-type="supplementary-material"}A-C). Patients with increased NLR had a poorer OS than those with low NLR (*P*=0.005 in the training set; *P*=0.014 in the validation set; *P*\<0.001 in the combined set; Figure [S1](#SM0){ref-type="supplementary-material"}D-F, respectively). Furthermore, further analysis showed that plasma fibrinogen had a positive and significant correlation with NLR (Table [S2](#SM0){ref-type="supplementary-material"}).

As shown in Figure [1](#F1){ref-type="fig"}A-C, patients with F-NLR 2 showed compromised OS compared to patients with F-NLR 0 or F-NLR 1 in the training (*P*\< 0.001), validation (*P*\< 0.001) and combined sets (*P*\<0.001).When stratified by pathological TNM stages (I, II and III) were analyzed separately, the OS of patients with F-NLR 0 or F-NLR 1 were higher than those with F-NLR 2 in stages I-II (*P*=0.030 in the training set; *P*=0.020 in the validation set; *P*\<0.001 in the combined set; Figure [2](#F2){ref-type="fig"}A-C, respectively) and stage III (*P*=0.001 in the training set; *P*\<0.001 in the validation set; *P*\<0.001 in the combined set; Figure [2](#F2){ref-type="fig"}D-F, respectively).

Univariate and multivariate regression analyses
-----------------------------------------------

To identify the independent prognostic indexes for OS, we carried out univariate and multivariate analyses with a Cox proportional hazard model. As shown in Table [2](#T2){ref-type="table"}, a high F-NLR score confirmed to be a significant negative prognostic factor in all 3 sets (*P*\<0.001). In addition, tumor size (*P*\<0.001 in all 3 sets), pathological TNM stages(*P*\<0.001 in all 3 sets), PLR (*P*=0.007 in the training set; *P*\<0.001 in the validation set; *P*\<0.001 in the combined set, respectively), LMR (*P*=0.015 in the training set; *P*=0.007 in the validation set; *P*=0.004 in the combined set, respectively) and SII (*P*=0.014 in the training set; *P*\<0.001 in the validation set; *P*\<0.001 in the combined set, respectively) was also proved to be significantly associated with OS. Moreover, Age (*P*=0.023) was identified to be significantly correlated with OS in the training set, as was surgical procedure in the validation set (*P*=0.049) and in the combined set (*P*=0.043).These indicators were then included into the multivariate Cox proportional hazards model, and we found that only F-NLR (*P*=0.007; *P*=0.003; *P*=0.002; Table [3](#T3){ref-type="table"}, respectively) and pathological TNM stages (*P*\<0.001) were independent prognostic factors for OS in all 3 sets. Tumor size was independent prognostic factor in the validation set (*P*=0.024) and in the combined set (*P*=0.042), but not in the training set (*P*=0.425).

Extension and accuracy of prognostic models with FNLR
-----------------------------------------------------

Because of the distinctly prognostic value, we united F-NLR into the pathological TNM staging system to evaluate the practical application of F-NLR. ROC analysis was applied to assess the prognostic accuracy. As shown in Figure [1](#F1){ref-type="fig"}D, the AUC of pathological TNM stage alone was 0.700 (95% CI: 0.646-0.754) as compared with 0.717 (95% CI: 0.664-0.770) for the F-NLR. When F-NLR were added into the pTNM staging system, the AUC was elevated to 0.803 (95% CI: 0.758-0.848).

F-NLR as a predictor for the choice of postoperative treatment patter in AEG and UGC patients
---------------------------------------------------------------------------------------------

In the subgroup analysis, we assessed the association between postoperative adjuvant chemotherapy and OS. In patients with F-NLR 0/1 could not benefit from adjuvant chemotherapy in training, validation and combined sets (*P*=0.827, *P*=0.483, *P*=0.500, Figure [3](#F3){ref-type="fig"}A-C, respectively). However, those patients with F-NLR 2 could benefit greatly from adjuvant chemotherapy (*P*=0.020, *P*=0.005, *P*\<0.001, Figure [3](#F3){ref-type="fig"}D-F, respectively).

Discussion
==========

Although with the rapid developments in surgical techniques and adjuvant treatments, the median survival of gastrointestinal malignancies remains unsatisfactory [@B27]. A proper prognostic factor can allow patients with tumors to have an appropriate risk classification and allow for the adequate treatment to be assigned. Cancer progression and prognosis are not just determined by clinical and pathological features of the tumor. Personalized factors can also play a central role in estimate of survival. In our current retrospective study, we investigated the prognostic value of F-NLR score and the relationship between F-NLR and clinicopathological features in the patients with pTNM stages I-III AEG and UGC.

Inflammation and immune cells are essential components of the tumor microenvironments. By creating a favorable microenvironment and inhibiting anti-tumor immunity, systemic inflammatory responses of tumor cells are important in tumor growth, progression and metastasis [@B28]. A growing of evidence suggests that systemic inflammation responses are key prognostic indicators [@B29], [@B30]. The systemic inflammatory response disrupts balance of circulating white blood cell components [@B31]. Thus, it affects the number of neutrophils and lymphocytes in leukocyte during cancer progression. The neutrophil- lymphocyte ratio (NLR) has been recognized as a representative prognostic indicator in various malignancies, including gastric cancer [@B32]-[@B34].

In addition, more and more studies have demonstrated that the association between haemostatic system and cancer progression in recent years [@B17], [@B18]. Increasing evidence performs that the activation of the haemostatic cascade plays a crucial pathophysiological role in tumor aggressiveness [@B35]. Fibrinogen is a main acute-phase protein and as an important component of the haemostatic system, has been shown to be a necessary regulator of the systemic inflammatory state and malignancy progression [@B36].It may mediate the original adhesion of white blood cells to endothelial cells and the release of pro-inflammatory cytokines, thus induce cancer cell proliferation and progression [@B37]. Hyperfibrinogenemia has been confirmed to be a significant prognostic predictor with tumor progression and poor response to chemotherapy in various malignancies [@B19]-[@B21].

Therefore, the combination serum fibrinogen and NLR (F-NLR) provides a good prognostic marker for cancer patients. Fibrinogen alone or NLR may have a limited effect on tumor progression. F-NLR increases the adverse effects of fibrinogen and NLR, ultimately increasing the predictive significance of cancer patients. Recently, the prognostic value of F-NLR was further demonstrated in various studies. Huang et al [@B22], proved that preoperative F-NLR scores can be a valuable prognostic marker for patients with early resectable non-small cell lung cancer. Kijima et al [@B23], reported that the F-NLR score is promising to be a predictor of therapeutic effects and prognosis in patients undergoing esophagectomy for advanced esophageal squamous cell carcinoma. Liu et al [@B24], demonstrated that F-NLR score independently predicts outcomes of patients with gastric cancer underwent curative surgery, consistent with the findings of our study. In the current study, we proved F-NLR as an independent prognostic factor for OS in AEG and UGC patients and integrated it into the pathological TNM staging system to improve its prognostic value. When the patients with different pathological TNM stages were analyzed separately, the F-NLR score still displayed potential prognostic value. Furthermore, we also found that the high-risk patients according to F-NLR 2 may benefit from postoperative adjuvant chemotherapy. Thus, to evaluate the pathological situation of tumor progression, preoperative FNLR levels counted from blood samples should be assessed. The fact that F-NLR score can be obtained from the routine blood sample makes it practical and inexpensive.

This study had several shortages. First of all, this study was a single institute, retrospective analysis and could not avoid the bias in population selection. Second, although we restricted some possible mixed factors, the hematologic cell counts can be influenced by several factors. Third, we were short of the follow-up information for disease-free survival, and our conclusions may be reinforced by using other methods of survival.

Conclusion
==========

The preoperative F-NLR score is an independent predictor of survival in patients who underwent curative surgery for AEG and UGC. As it is objectively measured and daily available, which may be a useful clinical biomarker for identifying patients at high prognostic risk and planning individualized treatment strategies for patients with AEG and UGC.
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![Survival curves of patients with AEG and UGC according to the combination of fibrinogen concentration and NLR (F-NLR). A-C, Overall survival (OS) of patients with F-NLR=0, F-NLR=1, and F-NLR=2 in the A, training set (n = 161, *P* \<0.001); B, validation set (n = 195, *P* \<0.001); and C, combined set (n = 356, *P* \<0.001). D, Receiver operating characteristic of TNM stage (area under the curve \[AUC\] = 0.700) vs F-NLR (AUC = 0.717) vs TNM stage +F-NLR (AUC = 0.803)](jcav10p5518g001){#F1}

![Survival curves based on the F-NLR of AEG and UGC patients (TNM stage I-III). A-C, Overall survival (OS) of patients with TNM stage I-II with F-NLR=0, F-NLR=1, and F-NLR=2 in the A, training set (*P* =0.030); B, validation set (*P* =0.020); and C, combined set (*P* \<0.001). D-E, Overall survival (OS) of patients with TNM stage III with F-NLR=0, F-NLR=1, and F-NLR=2 in the A, training set (*P*=0.001); B, validation set (*P* \<0.001); and C, combined set (*P* \<0.001).](jcav10p5518g002){#F2}

![Relationship between F-NLR and benefit from adjuvant chemotherapy in patents with F-NLR 0-1 and F-NLR 2. Patients with F-NLR 0-1 in the A, training set (*P*=0.827); B, validation set (*P*=0.483); and C, combined set (*P*=0.500). Patients with F-NLR 2 in the D, training (*P*=0.020) set; E, validation set (*P*=0.005); and F, combined set (*P*\<0.001).](jcav10p5518g003){#F3}

###### 

Clinicopathologic characteristics of AEG and UGC patients.

                          Training set   Validation set   Combined set                
  ----------------------- -------------- ---------------- -------------- ------ ----- ------
  All patients            161            100              195            100    356   100
  Sex                                                                                 
  Female                  35             21.7             41             21.0   76    21.3
  Male                    126            78.3             154            79.0   280   78.7
  Age(years)                                                                          
  \<60                    72             44.7             73             37.4   145   40.7
  ≥60                     89             55.3             122            62.6   211   59.3
  Tumor size(cm)                                                                      
  \<5                     74             46.0             88             45.1   162   45.5
  ≥5                      87             54.0             107            54.9   194   54.5
  Location                                                                            
  UGC                     95             59.0             132            67.7   227   63.8
  AEG                     66             41.0             63             32.3   129   36.2
  Differentiation                                                                     
  Well/Moderate           38             23.6             50             25.6   88    24.7
  Poor                    123            76.4             145            74.4   268   75.3
  Surgical procedure                                                                  
  Proxima gastrectomy     92             57.1             124            63.6   216   60.7
  Total gastrectomy       69             42.9             71             36.4   140   39.3
  NLR                                                                                 
  \<1.84                  77             47.8             83             42.6   160   44.9
  ≥1.84                   84             52.2             112            57.4   196   55.1
  Fibrinogen (g/L)                                                                    
  \<3.09                  76             47.2             94             48.2   170   47.8
  ≥3.09                   85             52.8             101            51.8   186   52.2
  PLR                                                                                 
  \<110                   76             47.2             78             40.0   154   43.3
  ≥110                    85             52.8             117            60.0   202   56.7
  LMR                                                                                 
  \<3.25                  53             32.9             47             24.1   100   28.1
  ≥3.25                   108            67.1             148            75.9   256   71.9
  SII                                                                                 
  \<451                   85             52.8             102            52.3   187   52.5
  ≥451                    76             47.2             93             47.7   169   47.5
  pTNM stage                                                                          
  I                       19             11.8             30             15.4   49    13.8
  II                      56             34.8             58             29.7   114   32.0
  III                     86             53.4             107            54.9   193   54.2
  F-NLR                                                                               
  0                       45             28.0             49             25.1   94    26.4
  1                       63             39.1             79             40.5   142   39.9
  2                       53             32.9             67             34.4   120   33.7
  Adjuvant chemotherapy                                                               
  Yes                     77             47.8             91             46.7   168   47.2
  No                      84             52.2             104            53.3   188   52.8

AEG: adenocarcinoma of esophagogastric junction; UGC: upper gastric cancer; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; LMR: lymphocyte-monocyte ratio; SII: (SII=N×P/L), which was based on neutrophil (N), platelet (P) and lymphocyte (L) counts; F-NLR: combination of fibrinogen concentration and neutrophil-lymphocyte ratio.

###### 

Univariate Cox regression analyse for OS.

                          Training set          Validation set   Combined set                                                                                                                                                                                                       
  ----------------------- --------------------- ---------------- -------------- --------------------- -------------- -------------- -------------- ------------- --------- ------------- --------- -- -- ------------- ----------- -- -- -- -- -- ------------- ----------- ------- --
  Sex                                                                                                                               0.463                                                                              0.367                                                0.775   
  Female                  1.00                                                                        1.00                                                       1.00                                                                                                               
  Male                    0.812                 0.467-1.415                                           1.284          0.746-2.208                                 1.058     0.719-1.557                                                                                              
  Age(years)                                                                                                                        **0.023**                                                            0.869                                                  0.102               
  \<60                    1.00                                                                        1.00                                                       1.00                                                                                                               
  ≥60                     1.733                 1.080-2.780                                           1.037          0.671-1.603                                 1.305     0.948-1.795                                                                                              
  Tumor size(cm)                                                                                                                    **0.001**                                                            **\<0.001**                              **\<0.001**                       
  \<5                     1.00                                                                        1.00                                                       1.00                                                                                                               
  ≥5                      2.247                 1.376-3.670                                           3.111          1.941-4.988                                 2.681     1.909-3.764                                                                                              
  Location                                                                                                                          0.927                                                                              0.088                                                0.083   
  UGC                     1.00                                                                        1.00                                                       1.00                                                                                                               
  AEG                     1.022                 0.646-1.615                                           1.461          0.945-2.260                                 1.320     0.965-1.807                                                                                              
  Differentiation                                                                                                                   0.243                                                                              0.215                                                0.094   
  Well/Moderate           1.00                                                                        1.00                                                       1.00                                                                                                               
  Poor                    1.402                 0.795-2.470                                           1.379          0.830-2.293                                 1.381     0.946-2.015                                                                                              
  Surgical procedure                                                                                                                0.415                                                                              **0.049**                                **0.043**           
  Proxima gastrectomy     1.00                                                                        1.00                                                       1.00                                                                                                               
  Total gastrectomy       1.207                 0.768-1.898                                           1.527          1.002-2.326                                 1.374     1.010-1.870                                                                                              
  NLR                                                                                                                               **0.006**                                                            **0.015**                                **\<0.001**                       
  \<1.84                  1.00                                                                        1.00                                                       1.00                                                                                                               
  ≥1.84                   1.941                 1.207-3.120                                           1.737          1.113-2.711                                 1.820     1.316-2.517                                                                                              
  Fibrinogen (g/L)                                                                                                                  **\<0.001**                                                          **\<0.001**                              **\<0.001**                       
  \<3.09                  1.00                                                                        1.00                                                       1.00                                                                                                               
  ≥3.09                   2.546                 1.539-4.212                                           2.606          1.648-4.122                                 2.598     1.851-3.645                                                                                              
  PLR                                                                                                                               **0.007**                                                            **\<0.001**                              **\<0.001**                       
  \<110                   1.00                                                                        1.00                                                       1.00                                                                                                               
  ≥110                    1.913                 1.190-3.076                                           2.750          1.669 4.533                                 2.229     1.592-3.122                                                                                              
  LMR                                                                                                                               **0.015**                                                            **0.007**                                **0.004**                         
  \<3.25                  1.00                                                                        1.00                                                       1.00                                                                                                               
  ≥3.25                   0.568                 0.360-0.897                                           0.536          0.340-0.844                                 0.620     0.449-0.855                                                                                              
  SII                                                                                                                               **0.014**                                                            **\<0.001**                              **\<0.001**                       
  \<451                   1.00                                                                        1.00                                                       1.00                                                                                                               
  ≥451                    1.771                 1.122-2.795                                           2.272          1.478-3.492                                 2.020     1.478-2.762                                                                                              
  pTNM stage                                                                                                                        **\<0.001**                                                          **\<0.001**                              **\<0.001**                       
  I                       1.00                                                                        1.00                                                       1.00                                                                                                               
  II                      4.133                 0.958-17.833     0.057                                6.394          1.497-27.299   0.012                        3.631     1.433-9.201   0.007                                                                                      
  III                     12.370 2.969-51.540   0.001                           15.255 3.728-62.423   \<0.001        9.580          3.910-23.471   \<0.001                                                                                                                          
  F-NLR                                                                                                                             **\<0.001**                                                          **\<0.001**                              **\<0.001**                       
  0                       1.00                                                  1.00                                                               1.00                                                                                                                             
  1                       4.029                 1.772-9.163      0.001                                3.252          1.511-6.998    0.003                        2.506     1.502-4.182   \<0.001                                                                                    
  2                       5.604                 2.502-12.554     \<0.001        5.534                 2.604-11.762   \<0.001        4.116          2.496-6.785   \<0.001                                                                                                            
  Adjuvant chemotherapy                                                                                                             0.202                                                                              0.146                                                0.106   
  Yes                     1.00                                                                        1.00                                                       1.00                                                                                                               
  No                      1.345                 0.853-2.121                                           1.368          0.896-2.088                                 1.290     0.868-1.608                                                                                              

OS: overall survival; HR: hazard ratio; CI: confidence interval; UGC: upper gastric cancer; AEG: adenocarcinoma of esophagogastric junction; NLR: neutrophil-lymphocyte ratio; PLR: platelet- lymphocyte ratio; LMR: lymphocyte-monocyte ratio; SII:(SII=N×P/L), which was based on neutrophil (N), platelet (P) and lymphocyte (L) counts; F-NLR: combination of fibrinogen concentration and neutrophil-lymphocyte ratio.

###### 

Multivariate Cox regression analyse for OS.

                        Training set          Validation set   Combined set                                                                                                                                                                                   
  --------------------- --------------------- ---------------- -------------- --------------------- -------------- -------------- -------------- ------------- ------- ------------- ------- -- -- ------------- ------- -- -- -- -- -- ------------- ------- --
  Age(years)                                                                                                                      0.644                                                                                                                       
  \<60                  1.00                                                                                                                                                                                                                                  
  ≥60                   1.129                 0.675-1.886                                                                                                                                                                                                     
  Tumor size(cm)                                                                                                                  0.425                                                            **0.024**                            **0.042**             
  \<5                   1.00                                                                        1.00                                                       1.00                                                                                           
  ≥5                    1.257                 0.717-2.202                                           1.784          1.079-2.949                                 1.455   1.015-2.088                                                                            
  Surgical procedure                                                                                                                                                                                             0.959                                0.730   
  Proxima gastrectomy                                                                               1.00                                                       1.00                                                                                           
  Total gastrectomy                                                                                 1.012          0.650-1.574                                 1.057   0.772-1.447                                                                            
  PLR                                                                                                                             0.612                                                            0.871                                0.327                 
  \<110                 1.00                                                                        1.00                                                       1.00                                                                                           
  ≥110                  1.160                 0.654-2.058                                           1.050          0.580-1.900                                 1.238   0.807-1.900                                                                            
  LMR                                                                                                                             0.052                                                            0.113                                0.271                 
  \<3.25                1.00                                                                        1.00                                                       1.00                                                                                           
  ≥3.25                 0.600                 0.359-1.005                                           0.674          0.414-1.098                                 0.820   0.576-1.167                                                                            
  SII                                                                                                                             0.320                                                            0.715                                0.863                 
  \<451                 1.00                                                                        1.00                                                       1.00                                                                                           
  ≥451                  1.403                 0.720-2.736                                           1.105          0.646-1.890                                 1.040   0.668-1.618                                                                            
  pTNM stage                                                                                                                      **\<0.001**                                                      **\<0.001**                          **\<0.001**           
  I                     1.00                                                                        1.00                                                       1.00                                                                                           
  II                    3.682                 0.834-16.250     0.085                                5.045          1.155-22.038   0.031                        2.774   1.079-7.134   0.034                                                                    
  III                   11.304 2.637-48.455   0.001                           10.634 2.489-45.433   0.001          6.118          2.418-15.478   \<0.001                                                                                                      
  F-NLR                                                                                                                           **0.007**                                                        **0.003**                            **0.002**             
  0                     1.00                                                  1.00                                                               1.00                                                                                                         
  1                     3.394                 1.417-8.129      0.006                                2.860          1.278-6.397    0.011                        1.921   1.124-3.283   0.017                                                                    
  2                     4.591                 1.776-11.866     0.002          4.432                 1.880-10.450   0.001          2.764          1.559-4.900   0.001                                                                                          

OS: overall survival; HR: hazard ratio; CI: confidence interval; UGC: upper gastric cancer; AEG: adenocarcinoma of esophagogastric junction; PLR: platelet-lymphocyte ratio; LMR: lymphocyte-monocyte ratio; SII:(SII=N×P/L), which was based on neutrophil (N), platelet (P) and lymphocyte (L) counts; F-NLR: combination of fibrinogen concentration and neutrophil-lymphocyte ratio.
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